Diana Chirovsky

826 total citations
43 papers, 461 citations indexed

About

Diana Chirovsky is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Diana Chirovsky has authored 43 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 18 papers in Surgery and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Diana Chirovsky's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Head and Neck Cancer Studies (15 papers). Diana Chirovsky is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Head and Neck Cancer Studies (15 papers). Diana Chirovsky collaborates with scholars based in United States, Spain and United Kingdom. Diana Chirovsky's co-authors include Jonathan D. Cheng, Mallika Lala, Kapil Mayawala, Robert Cody, Hemant Phatak, Javed Butler, Anne Marie McNeill, Vasilisa Sazonov, Yadong Cui and Philip J. Barter and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Diana Chirovsky

41 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diana Chirovsky United States	11	169	132	99	99	77	43	461
Arti Parekh United States	13	281 1.7×	415 3.1×	139 1.4×	32 0.3×	57 0.7×	19	792
Thomas M. Churilla United States	13	193 1.1×	191 1.4×	191 1.9×	81 0.8×	14 0.2×	33	548
Scott M. Atay United States	11	121 0.7×	225 1.7×	90 0.9×	14 0.1×	30 0.4×	49	433
P. P. A. Razenberg Netherlands	5	210 1.2×	270 2.0×	54 0.5×	18 0.2×	38 0.5×	7	463
Rebecca M. Prince Canada	9	131 0.8×	102 0.8×	81 0.8×	11 0.1×	55 0.7×	28	292
V.E.P.P. Lemmens Netherlands	13	498 2.9×	216 1.6×	268 2.7×	30 0.3×	34 0.4×	27	811
Jessica Wobb United States	14	118 0.7×	122 0.9×	201 2.0×	58 0.6×	31 0.4×	42	546
Claudia Bareggi Italy	12	516 3.1×	211 1.6×	106 1.1×	24 0.2×	31 0.4×	38	721
Weidong Kong Canada	11	598 3.5×	213 1.6×	383 3.9×	61 0.6×	37 0.5×	21	964
Esther van Meerten Netherlands	14	334 2.0×	204 1.5×	361 3.6×	81 0.8×	12 0.2×	37	618

Countries citing papers authored by Diana Chirovsky

Since Specialization

Citations

This map shows the geographic impact of Diana Chirovsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Chirovsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Chirovsky more than expected).

Fields of papers citing papers by Diana Chirovsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Chirovsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Chirovsky. The network helps show where Diana Chirovsky may publish in the future.

Co-authorship network of co-authors of Diana Chirovsky

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Chirovsky. A scholar is included among the top collaborators of Diana Chirovsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Chirovsky. Diana Chirovsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wagenius, Gunnar, Anders Vikström, Anders Berglund, et al.. (2025). Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer – a population-based cohort study in Sweden. Acta Oncologica. 64. 415–422. 2 indexed citations

Herbst, Roy S., Byoung Chul Cho, Mauricio Burotto, et al.. (2025). Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. Journal of Thoracic Oncology. 20(9). 1302–1314.

Donington, Jessica, Xiaohan Hu, Su Zhang, et al.. (2024). Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 25(5). 440–448. 1 indexed citations

Velcheti, Vamsidhar, et al.. (2024). 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC. Clinical Lung Cancer. 25(6). 502–508.e3. 10 indexed citations

Hu, Xiaohan, et al.. (2024). A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection. BMC Pulmonary Medicine. 24(1). 332–332. 1 indexed citations

Halmos, Balázs, et al.. (2024). Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors. Frontiers in Oncology. 14. 1285280–1285280. 2 indexed citations

Liu, Stephen V., et al.. (2024). Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutations. SHILAP Revista de lepidopterología. 3. 100024–100024. 1 indexed citations

Donington, Jessica, Xiaohan Hu, Su Zhang, et al.. (2023). Event-free survival as a predictor of overall survival and recurrence burden of patients with non–small cell lung cancer receiving neoadjuvant therapy. Journal of Thoracic and Cardiovascular Surgery. 168(4). 1261–1269.e1. 6 indexed citations

Black, Christopher M., et al.. (2022). Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis. Frontiers in Oncology. 12. 868490–868490. 2 indexed citations

10.

Hughes, Brett, René González Mendoza, Nicole Basset‐Séguin, et al.. (2021). Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629. Dermatology and Therapy. 11(5). 1777–1790. 9 indexed citations

11.

Prabhu, Vimalanand S., Sonya J. Snedecor, Shelby Corman, et al.. (2021). Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States. Frontiers in Public Health. 8. 624092–624092. 19 indexed citations

12.

Massetti, Massimo, et al.. (2020). PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France. Value in Health. 23. S436–S436. 2 indexed citations

13.

Grünwald, Viktor, Diana Chirovsky, Winson Y. Cheung, et al.. (2020). Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. Oral Oncology. 102. 104526–104526. 33 indexed citations

14.

Lala, Mallika, Diana Chirovsky, Jonathan D. Cheng, & Kapil Mayawala. (2018). Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review. Oral Oncology. 84. 108–120. 62 indexed citations

15.

Gruenwald, Viktor, Diana Chirovsky, Winson Y. Cheung, et al.. (2018). PCN11 - GLOBAL LONGITUDINAL ASSESSMENT OF TREATMENT OUTCOMES IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (GLANCE-H&N) STUDY. Value in Health. 21. S17–S17. 1 indexed citations

16.

Norquist, Josephine M., Diana Chirovsky, Teja Munshi, et al.. (2017). Assessing the Comparability of Paper and Electronic Versions of the EORTC QOL Module for Head and Neck Cancer: A Qualitative Study. JMIR Cancer. 3(1). e7–e7. 8 indexed citations

17.

Chirovsky, Diana, et al.. (2015). Inpatient Treatment Patterns and Health Care Expenditures for Hepatocellular Carcinoma among the Population with Urban Basic Health Insurance in China. Value in Health Regional Issues. 6. 132–140. 1 indexed citations

18.

Ambegaonkar, Baishali, Lori D. Bash, Diana Chirovsky, et al.. (2013). Attainment of normal lipid levels among high cardiovascular risk patients: Pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada. European Journal of Internal Medicine. 24(7). 656–663. 7 indexed citations

19.

Ambegaonkar, Baishali, et al.. (2010). The Effects of Isolated versus Multiple Lipid Disorders on Resource Utilization among Metabolic Syndrome Patients with Lipid Abnormalities despite Lipid-Modifying Treatment. Cardiology. 117(2). 96–104. 2 indexed citations

20.

Butler, Javed, Diana Chirovsky, Hemant Phatak, Anne Marie McNeill, & Robert Cody. (2010). Renal Function, Health Outcomes, and Resource Utilization in Acute Heart Failure. Circulation Heart Failure. 3(6). 726–745. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact